

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 July 03, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Swidler Stuart J

2. Issuer Name and Ticker or Trading Symbol  
 BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 \_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
 SVP, Clinical Affairs

(Last) (First) (Middle)  
 C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 07/02/2007

NOVATO, CA 94949  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code	V	Amount or Price			
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	M		12,500	A \$ 4	22,500	D	
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S		100	D \$ 18.12	22,400	D	
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S		1,150	D \$ 18.121	21,250	D	
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S		450	D \$ 18.131	20,800	D	
	07/02/2007 <sup>(1)</sup>	07/02/2007	S		300	D \$ 18.14	20,500	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	600	D	\$ 18.15	19,900	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	1,750	D	\$ 18.161	18,150	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	900	D	\$ 18.17	17,250	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	1,250	D	\$ 18.09	16,000	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	300	D	\$ 18.151	15,700	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	200	D	\$ 18.16	15,500	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	1,100	D	\$ 18.18	14,400	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	450	D	\$ 18.181	13,950	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	200	D	\$ 18.19	13,750	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	400	D	\$ 18.2	13,350	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	450	D	\$ 18.201	12,900	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	400	D	\$ 18.21	12,500	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	100	D	\$ 18.26	12,400	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	1,150	D	\$ 18.261	11,250	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	100	D	\$ 18.27	11,150	D
Common Stock	07/02/2007 <sup>(1)</sup>	07/02/2007	S	1,150	D	\$ 18.271	10,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock Option (right to buy)	\$ 4	07/02/2007	07/02/2007	M	12,500	12/24/1998 <sup>(2)</sup> 06/14/2008	Common Stock	12,500

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Swiedler Stuart J C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Clinical Affairs	

**Signatures**

/s/ G. Eric Davis,  
Attorney-in-Fact  
07/03/2007  
Date

\*\*Signature of Reporting Person

**Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Rule 10b5-1 Trading Plan.
- (2) Options vest 6/48ths on 12/24/1998 and 1/48th on the 24th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.